

**D. Remarks****1. Claim amendments**

Claims 80, 81, 82, 83, 84, 86 and 97 are presently amended. Claims 81-84 are amended to place these in independent form. Claims 86 and 97 are amended to correct dependency.

Claim 80 is amended to recite the definition of highly stringent conditions that is set forth at page 13 of the specification. Further, the claim now requires that the nucleic acid molecule hybridize to the complement of SEQ ID NO: 15, rather than any of SEQ ID NOS: 4, 8 and 15. Further, the claim states that the nucleic acid molecule must encode a cancer associated antigen. See example 10, and pages 16-17 of the specification. The terminology used in the claim reflects that found in, e.g., the claims of US Patent Nos. 6,297,364 and 6,576,756.

Amendment of claims 81, 82, 83, 84 and 86 obviates the objections to the claims.

The recitation of stringent conditions obviates the rejection bridging pages 3-4 of the specification.

With respect to the written description rejection, it is believed that given the amendment to the claims, the rejection cannot be maintained. Specific hybridization conditions are given, as is a function for the molecules claimed. The specification makes clear what the function of the molecules claimed are.

Example 9 of the "Revised Interim Guidelines for Compliance with the Written Description Requirement" is clearly on point, and supports the amendment. All of these factors make it incumbent upon the examiner to withdraw the written description requirement rejection.

With respect to the prior art rejection, the cancellation of SEQ ID NO: 4 in claim 80 overcomes this rejection.

2. Specification Amendment

The sequence listing has been replaced so that both the paper copy and computer readable form are in agreement with the specification. The two other specification amendments requested by the examiner have been made.

\* \* \* \* \*

No other issues are presented.

Allowance of this application is believed proper, and is urged.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

A handwritten signature in black ink, appearing to read 'Norman D. Hanson', is written over a horizontal line.

Norman D. Hanson, Esq.  
Registration No. 30,946

666 Fifth Avenue  
New York, New York 10103-3198  
Phone: 212-318-3168  
Fax: 212-318-3400

**C. Amendment to Drawing Figures**

None.